factory supply Trilostane CAS NO.13647-35-3

Min.Order: 1 Kilogram
Payment Terms: L/C,T/T,Other

Product Details

Keywords

Trilostane
3β-hydroxysteroid dehydrogenase
13647-35-3

Quick Details

ProName: factory supply Trilostane
CasNo: 13647-35-3
Molecular Formula: C20H27NO3
Appearance: White crystallization
Application: the treatment of Cushing's syndrome an...
DeliveryTime: in two weeks
PackAge: 25kg/drum
Port: SHANGHAI BEIJING
ProductionCapacity: 10 Metric Ton/Day
Purity: USP/EP/BP
Storage: room temperature
Transportation: AIR SEA TRAIN
LimitNum: 1 Kilogram

Superiority

We are very compeitive on Trilostane

Product Name:	Trilostane
CAS:	13647-35-3
MF:	C20H27NO3
MW:	329.43
EINECS:	237-133-0
Product Categories:	Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Inhibitor;FULVICIN
Mol File:	13647-35-3.mol

Details

Trilostane Chemical Properties

Melting point	264 °C
alpha	D25 +137.4° (c = 1 in pyridine)
Boiling point	467.02°C (rough estimate)
density	1.1213 (rough estimate)
refractive index	1.5614 (estimate)
storage temp.	2-8°C
solubility	DMSO: ≥17mg/mL
pka	8.57±0.70(Predicted)
form	powder
color	white to tan
CAS DataBase Reference	13647-35-3(CAS DataBase Reference)
EPA Substance Registry System	Trilostane (13647-35-3)

Trilostane Usage And Synthesis

treatment of Cushing's syndrome

Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome and primary hyperaldosteronism. These are both disorders where excess amounts of corticosteroid hormones are produced in the body. Corticosteroids are essential for the body to make use of carbohydrates, fats and proteins and for a normal response to stress. They are also necessary for the regulation of salt and water balance in the body. Trilostane helps prevent the production of corticosteroids, controlling the symptoms associated with these disorders.
Trilostane can also be useful in the treatment of breast cancer that has relapsed in women who have gone through menopause.

Uses in dogs

Trilostane was withdrawn from the United States market in April 1994. However, it was approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs.
It is also the first drug approved to treat both pituitary-and adrenal-dependent Cushing's in dogs.
1. has kidney or liver disease.
2. takes certain medications used to treat heart disease.
3. pregnant.
4. taking other medicines, including those available to buy without a prescription, herbal or complementary medicines.
5. had an allergic reaction to this or any other medicine.

factory supply Trilostane CAS NO.13647-35-3

Keywords

Quick Details

Superiority

Details

Other products of this supplier